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Abstract
The Abbott Real-Time HIV-1 assay was evaluated for its perfor-
mance in quantiﬁcation of human immunodeﬁciency virus type 1
(HIV-1) RNA in dried blood spot (DBS) samples. In total, 169 blood
samples with detectable plasma HIV-1 RNA were used to extract
RNA from paired DBS and liquid plasma samples, using the auto-
mated Abbott m Sample Preparation System (m2000sp). HIV-1
RNAwas then quantitated by the m2000rt RealTime analyser. RNA
samples suitable for real-time PCR were obtained from all but one
(99.4%) of the DBS samples and HIV-1 RNA was detected in 163/
168 (97.0%) samples. The correlation between HIV-1 RNA values
measured in paired DBS and plasma samples was very high
(r = 0.882), with 78.5% and 99.4% of cases differing by <0.5 and
1.0 log, respectively. Retesting of DBS replicates following 6months
of storage at 2–8C showed no loss of HIV-1 RNA in a subset of 89
samples. The feasibility of DBS testing coupled with automated sam-
ple processing, and the use of a latest-generation FDA-approved
real-time PCR-based system, represents an encouraging ﬁrst step
for viral load measurement in reference centres in developing coun-
tries where access to antiretroviral therapy is expanding.
Keywords: Antiretroviral therapy, dried blood spot, human
immunodeﬁciency virus, monitoring, viral load assay
Original Submission: 11 June 2008; Revised Submission:
3 July 2008; Accepted: 3 July 2008
Editor: E. Gould
Clin Microbiol Infect 2009; 15: 93–97
10.1111/j.1469-0691.2008.02116.x
Corresponding author and reprint requests: M. Zazzi, Division
of Microbiology, Department of Molecular Biology, University of Sie-
na, Viale Bracci 1, 53100 Siena, Italy
E-mail: zazzi@unisi.it
The epidemic of human immunodeﬁciency virus type 1 (HIV-1)
infection in Africa and other countries with limited health-
care resources remains a major cause of morbidity and mor-
tality [1]. The elevated cost of antiretroviral drugs has been
one of the main obstacles to the control of the epidemic in
these areas. Nonetheless, there is now increasing access to
antiretroviral therapy through health programmes funded by
the WHO and national health services, as well as through
international charity foundations [2]. Systematic monitoring
of viral load, as measured by plasma HIV-1 RNA amount, is
the standard method for verifying adequate control of viral
replication in patients under antiretroviral treatment (http://
www.aidsinfo.nih.gov/Guidelines/). Indeed, viral load has been
shown to be predictive of clinical progression, and to change
promptly in response to treatment success or failure. Thus,
expanding access to antiretroviral therapy in developing
countries must be supported by the availability of methods
to quantify viral load. However, monitoring of viral load in
countries with limited resources poses logistical challenges.
Relatively few laboratories that have the capacity to perform
molecular diagnostics exist. Such laboratories are often
distant from rural communities, which account for a large
proportion of the population. The difﬁculty in ensuring the
necessary conditions of transport between the site of blood
sampling in local dispensaries and the monitoring laboratory
may preclude routine assay of liquid plasma samples. In addi-
tion, access to a reliable source of electricity and to clean
water may be limited in rural areas.
One solution that has been proposed for improving access
to viral load monitoring in such countries is the use of dried
blood samples [3–10]. A drop of blood can be obtained in
the ﬁeld from a ﬁnger prick, applied to a piece of ﬁlter
paper, air-dried, and stored until measurement of HIV-1
RNA. It has been demonstrated that HIV-1 RNA in dried
blood spot (DBS) samples is stable over time under differing
conditions of temperature and humidity [4,6,9]. The feasibil-
ity of HIV-1 RNA testing in DBS samples that can be easily
transported makes possible the establishment of reference
centres where state-of-the-art molecular diagnostics can be
used to quantify HIV-1 RNA in patients scattered throughout
large geographical areas.
FDA-approved methods for quantiﬁcation of HIV-1
RNA were introduced in 1996 [11]. Since then, molecular
diagnostic methods have evolved considerably. Nowadays,
real-time ampliﬁcation, coupled with automated extraction,
offers several advantages over conventional PCR, including
a lower risk of contamination, a more rapid turnover time,
less stringent requirements concerning technical skills on
the part of operators, and an extended dynamic range
[12,13].
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Although real-time PCR has become the preferred tech-
nology for quantiﬁcation of HIV-1 RNA in a clinical diagnos-
tic setting, there have been no reports of its use with DBS
samples. The objective of this study was to evaluate the fea-
sibility of using the Abbott Real-Time HIV-1 assay to quantify
HIV-1 RNA load in DBS samples, as compared with liquid
plasma samples, in an Italian test population.
The study was conducted at two HIV reference centres in
Italy at the University Hospitals of Modena and of Siena. Ci-
trated blood samples were collected from the HIV-1-infected
patients presenting at one of the two study centres during a
pre-established enrolment period who were found to har-
bour at least 200 copies/mL of plasma HIV-1 RNA. The total
number of patients enrolled was 169 (95 in Modena and 74
in Siena). The study protocol was approved by the local eth-
ics committee, and all patients gave informed consent to par-
ticipate in the study. One millilitre of plasma was assayed for
detection of HIV-1 RNA, as usual after a single freeze–thaw
cycle. Two or four further 50-lL aliquots of whole blood
were applied to Whatman 903 ﬁlter-paper cards, which
were stored for a variable duration (median, 26 days; range,
1–170 days) at room temperature before assay. A subset of
89 samples, for which multiple DBS samples were obtained
at collection, was used to investigate the stability of HIV-1
RNA in DBS samples for 6 months at 2–8C.
For the DBS samples, a half-inch disk entirely covered
with the sample was cut from each spot. Two disks (one
each from the two spots prepared from the same patient)
were incubated in 2 mL of mLysis buffer provided with the
Abbott m Sample Preparation System (m2000sp) in 50-mL
sealed conical tubes. The tubes were incubated at room
temperature for 2 h, with intermittent mixing, and the entire
contents were then transferred to an m2000sp reaction ves-
sel. The lysate was processed according to the standard
HIV-1 RNA 1.0-mL extraction protocol as described else-
where [12]. The paired liquid plasma samples were tested,
placing them directly into the m2000sp apparatus, using the
same 1.0-mL routine protocol. The m2000sp then mixed the
RNA extracts obtained with the ampliﬁcation reagents and
dispensed the resulting reaction mixtures onto the Abbott
96-Well Optical Reaction Plate. An armoured RNA sequence
[14] unrelated to the HIV-1 target sequence was introduced
into each specimen at the beginning of sample preparation as
an internal control. A negative control (HIV-1-negative
human plasma) and a low and a high positive control (non-
infectious armoured RNA with inserted HIV-1 target
sequences diluted in HIV-1-negative human plasma) were
included in each test run for assay validation.
The 96-well m2000sp reaction plate was transferred to
the m2000rt RealTime analyser for RT-PCR ampliﬁcation of
HIV-1 RNA. The amount of HIV-1 target sequence that is
present at each ampliﬁcation cycle is quantiﬁed by measuring
the ﬂuorescence of the HIV-1 probe that binds to the target
during the extension/anneal step. The 1.0-mL HIV-1 RNA
protocol was used in accordance with the manufacturer’s
instructions. Fluorescence counts were converted directly
into viral load measures by the m2000rt analyser. The results
obtained with the DBS samples were corrected in order to
take into account the different input volumes used. A cor-
rection factor based on the difference between liquid plasma
and dry spot measurements of the high positive kit control,
tested in duplicate in each run, was calculated. This factor
was highly reproducible; its mean ± SD in ﬁve runs was
1.94 ± 0.06 log copies/mL. On the basis of this evidence and
additional in-house data, Abbott Molecular has made avail-
able an m2000 DBS HIV-1 RNA ‘open-mode’ protocol with
a software-embedded correction factor, so that no manual
data correction is needed before releasing the results.
CIs of the proportion of samples with detectable HIV-1
RNA were computed by the modiﬁed Wald method [15].
Log-transformed viral loads measured in the DBS samples
and in the paired liquid plasma samples were compared by
Pearson correlation analysis. Potential deviations from a sto-
chastic distribution of difference estimates between the two
types of sample were evaluated using Bland–Altman plots
[16]. Correlation analysis was also used to compare paired
measurements obtained on the same subset of DBS samples
assayed before and after 6 months of storage at room tem-
perature.
The automated RNA extraction from DBS samples failed
to yield material suitable for real-time PCR analysis in only
one of the 169 (0.6%) samples tested. HIV-1 RNA was
detected in 163 of the 168 DBS samples, with 97.0% sensitiv-
ity (Table 1). The correlation between viral load values
obtained from the paired 163 liquid plasma and DBS samples
was high (Pearson product–moment correlation coefﬁ-
cient = 0.882). Linear regression analysis of the viral loads
obtained with the two types of sample yielded a slope of
0.852 and an intercept of 0.616 (Fig. 1). The mean ± SD dif-
TABLE 1. Human immunodeﬁciency virus type 1 RNA
detection rates in paired dried blood spot (DBS) and liquid
plasma samples
Viral load in liquid
plasma
No. of
samples DBS-positive
Detection rate,
% (95% CI)
200–1000 copies/mL 20 18 90.0 (68.7–98.4)
1000–10 000 copies/mL 57 54 94.7 (85.1–98.8)
10 000–100 000 copies/mL 75 75 100.0 (94.2–100.0)
>100 000 copies/mL 16 16 100.0 (77.3–100.0)
All samples 168 163 97.0 (93.0–98.9)
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ference between the viral load measured in the DBS samples
and that determined in liquid plasma was 0.01 ± 0.39 log
copies/mL. Overall, viral load values in the two sample types
differed by less than half a log unit in 78.5% (128/163) of the
samples and by less than one log unit in 99.4% (162/163) of
the samples. However, the differences between DBS and
plasma HIV-1 RNA were higher in the 200–1000 copies/mL
range, as compared with the >1000 copies/mL group (-
mean ± SD = 0.50 ± 0.35 vs. )0.05 ± 0.35; p <0.001)
(Fig. 2).
To assess the stability of HIV-1 RNA in DBS samples, a
subset of 89 samples with multiple spots was retested after
6 months of storage at 2–8C, following the ﬁrst DBS analy-
sis. The correlation coefﬁcient derived from the two consec-
utive measurements was 0.955, with a slope of 0.963 and an
intercept of 0.150 (Fig. 3). The mean (±SD) difference
between the ﬁrst and second measurement was 0.01
(±0.22) log. All of the paired values were within 1 log differ-
ence, and only ﬁve (5.6%) samples differed by >0.5 log.
The feasibility study reported here demonstrates, for the
ﬁrst time, that HIV-1 RNA can be quantiﬁed in DBS samples
using a state-of-the-art FDA-approved real-time PCR assay,
the Abbott Real-Time HIV-1 assay. Although the samples
analysed were obtained from patients living in an area where
HIV-1 subtype B is still highly prevalent, the choice of this
assay from among the latest-generation systems was based
on its excellent performance in assessing different HIV-1
groups and subtypes in previous studies [12,17]. Indeed, the
highly diversiﬁed nature of HIV-1 in most of the developing
countries [18] poses a major challenge to accurate quantiﬁ-
cation of all the distinct genetic variants and requires rigor-
ous validation of any assay in this context.
This study revealed a very good correlation between
liquid plasma and DBS measurements, an excellent RNA sta-
bility over a 6-month period, and a deﬁnitely acceptable
threshold of sensitivity in light of the source material and the
clinical setting in which this assay would be used. Although a
formal deﬁnition of the lower limit of quantiﬁcation has not
been established at this stage, a 90% detection rate was
achieved with samples containing 200–1000 copies of HIV-1
RNA/mL, a performance comparable to, or better than, that
FIG. 1. Correlation between human immunodeﬁciency virus type 1
(HIV-1) RNA levels measured with the Abbott Real-Time assay in
dried blood spot (DBS; y-axis) and liquid plasma (x-axis) samples.
Each data point represents one of the 163 individual study samples.
The line indicates the best ﬁt of the data to a linear regression. The
Pearson correlation coefﬁcient determined from the linear regres-
sion analysis is 0.883.
FIG. 2. Bland–Altman analysis of the difference in human immunode-
ﬁciency virus type 1 (HIV-1) RNA levels measured with the Abbott
Real-Time assay in dried blood spots (DBS) and liquid plasma sam-
ples plotted as a function of HIV-1 RNA levels measured in the
liquid plasma samples. Each data point represents one of the 163
individual study samples.
FIG. 3. Correlation between repeated measurements of human
immunodeﬁciency virus type 1 (HIV-1) RNA levels in dried blood
spot (DBS) samples with the Abbott Real-Time assay. Each data
point represents one of the 89 individual study samples tested at the
beginning of the study and following 6 months of storage at 2–8C.
The line indicates the best ﬁt of the data to a linear regression. The
Pearson correlation coefﬁcient determined from the linear regres-
sion analysis is 0.955.
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of the ﬁrst-generation assays successfully used in Western
countries for several years. Nevertheless, the limited amount
of sample analysed by DBS testing necessarily leaves a small
proportion of patients in whom detection of early treatment
failure can be achieved with standard plasma testing but not
with the DBS assay. Although the blood adsorption capacity
of the ﬁlter paper disks does not allow the use of larger
amounts of blood, the overall sample volume could be
increased by using multiple spots. However, the amount of
lysis buffer should also be increased, due to augmented
paper adsorption. Thus, the possibility of obtaining a more
concentrated RNA sample needs to be carefully investigated.
A larger difference between DBS and plasma HIV-1 RNA
was noticed in the 200–1000 copies/mL range than in the
>1000 copies/mL samples; this may be explained by the con-
tribution of intracellular HIV-1 DNA and RNA which, by def-
inition, is present in the DBS but not in the plasma
counterpart. As intracellular HIV-1 DNA and RNA may be
detectable at low or undetectable levels of plasma viraemia
[19–21], their contribution could be more relevant to these
samples than to samples containing higher levels of extracel-
lular HIV-1 RNA. Formal quantitative analysis of cellular HIV-
1 DNA and RNA, as opposed to plasma HIV-1 RNA, in sam-
ples to be analysed in the form of DBS samples and plasma
is required to evaluate this hypothesis.
This study was undertaken as a ﬁrst step to assess the
feasibility of DBS testing by an FDA-approved latest-gener-
ation real-time PCR-based system. Although excellent
results have been shown here, several additional factors
must be considered in the application of this strategy in
developing countries. First, the storage conditions evaluated
here may be different from those required in some spe-
ciﬁc settings. Although HIV-1 RNA has been shown to be
stable in DBS samples under different temperature and
storage conditions, in this and previous studies [4,6,9], it
will be important to replicate the current results in a
tropical setting, using routine operational and logistic pro-
cedures. Second, an automated RNA extraction system
was used, according to current recommendations, to mini-
mize human intervention and operator-dependent variabil-
ity. Although the same strategy may be conceivable for
reference centres in developing countries, with the advan-
tage of a decreased need for major investment in skilled
personnel, local policies may prevent the equipment of lab-
oratories with automated sample-processing instruments.
Thus, the reproducibility of DBS analysis should be tested
with commonly used and effective manual RNA extraction
protocols [22]. In this context, Abbott Molecular is provid-
ing a certiﬁed manual extraction method as an alternative
to automated processing (Abbott Real-Time HIV-1 Package
Insert; Abbott Molecular Inc., Des Plaines, IL, USA, May
2007). Notwithstanding the need for further analysis, quan-
tiﬁcation of HIV-1 RNA in DBS samples by the Abbott
Real-Time HIV-1 assay appears to be a promising strategy
to support the expanding access to antiretroviral therapy
in developing countries.
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Abstract
On December 2006, an outbreak of gastroenteritis occurred at
a residential-care facility for the elderly in northern Italy. Thirty-
ﬁve of 61 individuals interviewed (attack rate, 57.4%) fell ill.
In 94.3% of cases, the onset of illness was within 48 h of a
Christmas party at the facility. Norovirus (NoV) was detected
by RT-PCR in 24 of 31 individuals examined, including three
asymptomatic food-handlers, in whom there was evidence of
long-lasting excretion of viral particles. The identiﬁcation of a
sequence referring to the ‘2006a GII.4 NoV variant’ in all exam-
ined strains supported the hypothesis of a common point
source. This retrospective cohort study is the ﬁrst report on an
outbreak of NoV gastroenteritis in an Italian residential-care
facility for the elderly.
Keywords: Asymptomatic infection, norovirus outbreak,
residential-care facility, sequence analysis, virus shedding
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Outbreaks of gastroenteritis due to norovirus (NoV) often
occur during the winter months, and take place in closed
and semi-closed settings. This retrospective cohort study
describes an outbreak of gastroenteritis caused by NoV at a
residential-care facility for the elderly in northern Italy. On
22 December 2006, the manager of the facility reported the
occurrence of several cases of acute gastroenteritis among
residents. All individuals had attended a Christmas party on
20 December at the facility. A case was deﬁned as an illness
in any resident, staff member or guest who took part in the
event and experienced diarrhoea (three or more loose
stools within 24 h) and/or vomiting. The food served on that
occasion by individual serving (different food for residents
and for staff members and guests) was suspected to be
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